Eleven pediatric patients, aged 1 to 10 years and with symptomatic human immunodeficiency virus infection, were treated with 6 or 10 mg of oral ribavirin per kg of body weight daily for 60 days. Safety and pharmacokinetic parameters were monitored; five children had comprehensive pharmacokinetic evaluations. The children tolerated the drug well, and treatment was not associated with any clinically significant adverse effects. Peak concentrations in plasma of 2.5 and 3.0 ,uM were reached at 90 min after single oral doses of 6 and 10 mg/kg, respectively. The mean systemic availability of oral ribavirin was 42.3%. After 60 days of ribavirin administration, mean trough concentrations in plasma of 2.6 and 4.1 ,uM were obtained. Ribavirin penetrated well into the cerebrospinal fluid, achieving 70% of the concentration in plasma at steady state.
Ribavirin (1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide), a broad-spectrum antiviral agent structurally related to guanosine, has activity in vitro against both RNA and DNA viruses (12, 24, 34, 35) . Bunyaviruses, including those that cause Rift Valley fever and hemorrhagic fever with renal syndrome, are particularly susceptible to the antiviral action of ribavirin (24) . Systemic ribavirin has been used for the treatment of a variety of viral illnesses, including Lassa fever, measles, and hepatitis A (12, 13, 20, 22, 30, 34, 35) . Aerosol ribavirin is currently licensed in the United States for the treatment of respiratory syncytial virus infections in children and has been demonstrated to be useful in the treatment of influenza viruses A and B (15, 26, 34, 35 ).
Ribavirin's broad antiviral spectrum includes activity against human immunodeficiency virus type 1 (HIV). Concentrations of .50 ,ug/ml (205 ,uM) have been shown to suppress HIV replication in T-lymphocyte cultures, and concentrations as low as 10 ,ug/ml (41 ,uM) have been shown to suppress expression of HIV proteins in chronically infected cells (21, 31, 34) . Recent evidence suggests that ribavirin acts as an inhibitor of HIV reverse transcriptase (11) . Initial studies have suggested that doses above the maximum tolerated dose for HIV-infected adults (2,400 mg/day) are required to achieve levels of ribavirin in plasma approximating the 50% inhibitory concentration for HIV (17, 31) . However, evidence of reverse transcriptase inhibition has been observed at steady-state concentrations of >6 ,uM (29) .
Clinical trials of ribavirin in HIV-infected adults have been controversial and disappointing (5, 10, 11, 17, 27, 28, 29, 31, 36) . Although doses of 800 to 1,200 mg/day appear to be generally well tolerated in patients with lymphadenopathy and those with AIDS-related complex, the efficacy of ribavirin as a treatment for HIV infection has not been established. Initial studies suggested that ribavirin may have promise as single-agent antiretroviral therapy, but recent data have failed to demonstrate any consistent antiviral effect at clinically tolerated doses. The role of ribavirin in combination antiretroviral therapy is also unclear. Although the drug is antagonistic when tested in vitro with zidovudine, at least one study has suggested that ribavirin enhances the antiretroviral activity of purine analogs such as 2'3'-dideoxyinosine (ddl) (2, 3, 4, 37) .
Apart from the potential use as an antiretroviral agent, the broad antiviral spectrum of ribavirin makes it a potentially useful drug in the treatment of serious viral infections that may occur in immunocompromised patients, including children with HIV infection. Respiratory viruses such as respiratory syncytial virus, influenza virus, parainfluenza virus, and measles virus are important causes of morbidity and mortality in immunocompromised hosts and may be amenable to aerosol or systemic ribavirin therapy (7, 16, 19, 32) . Progressive and ultimately fatal cases of measles are being reported with increasing frequency among HIV-infected children (16, 19, 32) . Theoretically, ribavirin may play a role in the management of disease in these children, for whom alternative treatment is not available.
Ribavirin in HIV-infected children has not been previously studied. Before During the course of the trial, immunologic and retrovirologic parameters were measured monthly. Lymphocyte phenotyping was performed by standard flow cytometry techniques (14) . The presence of p24 antigen in serum was determined by a commercially available sandwich solidphase immunoassay (Abbott Laboratories, Chicago, Ill.). Quantitative immunoglobulins were measured in a commercial laboratory (Roche, Nutley, N.J.) by standard turbidometric techniques (8) .
RESULTS
The characteristics of the 11 children enrolled are listed in Table 1 . Five patients between the ages of 16 and 61 months received 6 mg of ribavirin per kg per day, and six patients between 12 and 123 months of age received 10 mg/kg/day. One patient missed a single oral dose of ribavirin during the daily-dosing segment of the study, and ribavirin treatment was discontinued for one patient after 38 days of daily dosing because of a possible adverse reaction.
Eleven children received a single oral dose of ribavirin at the start of the study (Table 2 ). Blood samples were first obtained from children under the age of 3 years for measurement of the ribavirin concentration at 2 h after the dose was given. Five children received 6 mg of oral ribavirin per kg. These included two males and three females, with a mean age of 26.2 months (16 to 61 months). Following a single oral dose, the mean concentration of ribavirin in plasma measured at 1 to 2 h after administration of the drug for the group was 2.5 ,uM (1.02 to 3.96 ,uM). Six patients (three male and three female), with a mean age of 52 months (12 to 123 months), received 10 mg/kg. The mean concentration in plasma for this group 1 to 2 h after a single oral dose was 3.05 p,M (1.09 to 4.34 ,uM). There were five children who were older than 3 years and who therefore had the most comprehensive sampling for pharmacokinetic analysis (Table 3) . Two patients received 6 mg and three patients received 10 mg of ribavirin per kg. In this group, the time to peak concentration in plasma was 1.8 (Table 3) .
excreted in urine at 48°C) for patients no. 4 and 11 were 0.3 The mean bioavailability of oral ribavirin among these and 0.1 liters/h/kg, respectively. patients was 42.3% (33.6%).
Safety and tolerance. All children tolerated ribavirin treatSteady-state ribavirin concentrations are listed in Table 4 . ment well. None experienced gastrointestinal disturbances, After 60 days of ribavirin administration, the peak ribavirin and there were no significant drug-associated changes in any concentrations in plasma ranged from 4 to 22 ,uM among of the following: weight, vital signs, physical examination, those receiving the drug orally. Mean trough concentrations chest X ray, electrocardiogram, electrolytes in serum, blood in plasma for the patients receiving doses of 6 and 10 mg/kg urea nitrogen, creatinine, lactate dehydrogenase, calcium, were 2.6 (SD, 0.5) and 4.1 (SD, 2.0) ,uM, respectively. Mean phosphorus, total protein, or albumin. trough CSF concentrations for children treated with 6 and 10
One patient who received 10 mg/kg had a mild (<3 times mg of ribavirin per kg for 60 days were 1.5 (SD, 0.6) and 3.0 the upper limit of normal for age), transient increase in One patient developed hematuria after 38 days of oral dosing with ribavirin (10 mg/kg), and the drug treatment was discontinued. Review of the records of his previous hospitalizations revealed that he had microscopic hematuria on two other occasions 9 4:+ral months prior to enrollment into the study. A kidney -liopsy, performed 3 months after discontinuation of ribavirin treatment, demonstrated mesangial proliferative glomerulonephritis, consistent with HIV nephropathy.
HIV parameters. Immunologic and retrovirologic monitoring revealed no consistent changes in quantitative immunoglobulins, median CD4 lymphocyte count, or serum p24 antigen detection during the course of ribavirin treatment. Although the numbers of patients in each treatment group were small, there appeared to be a trend toward decline of total lymphocyte count after 60 days of ribavirin dosing at 10 mg/kg. Patients who orally received 6 mg of ribavirin per kg for 60 days had a decline in their median lymphocyte counts of 9% (median count on day 0, 4,018 cells per mm3; median count on day 60, 3,690 cells per mm3). In contrast, children who received 10 mg/kg for 60 days had a decline of 66% (median count on day 0, 7,191 cells per mm3; median count on day 60, 2,695 cells per mm3).
DISCUSSION
Although there was notable interpatient variability, this pilot study suggests that ribavirin pharmacokinetics in symptomatic, HIV-infected children are similar to those reported previously for asymptomatic adults. Following a single oral dose of 6 to 10 mg/kg in children, peak ribavirin concentrations in plasma were 2.5 to 3.0 ,uM, slightly higher than those reported for adults (1.75 to 1.82 ,uM) receiving 400 to 600 mg (approximately 6 to 8.5 mg/kg). Time to peak concentration (1 to 2 h) and bioavailability (42%) values were identical to published adult values, despite the fact that some of the children in the present study had evidence of advanced HIV disease, including failure to thrive. The mean distribution t1/2 was 30 min, and the mean terminal t1/2 was prolonged at 18 h. This latter value is less than the 30 h reported by Lertora et al. for adults receiving a 400-mg (approximately 6-mg/kg) dose of ribavirin. This is a reflection of the smaller weightnormalized volume and higher weight-normalized CL found in the present study compared with the study of Lertora et al.
Studies with adults have previously demonstrated that ribavirin penetrates the blood-brain barrier (9) . Data from the present study confirm that ribavirin penetrates into the central nervous systems of pediatric patients well, with a mean CSF/plasma ratio of 0.7. As previously reported for animals and humans, urinary excretion appears to be a major route for ribavirin elimination. Rates of urinary recovery of ribavirin over 48 h in the two children studied were 38 and 41%. Ribavirin accumulated in RBC following repetitive oral dosing in children. At steady state, the RBC/plasma ratios for patients receiving 6 and 10 mg/kg were 70:1 to 80:1. Although insufficient steady-state data for comparison with single-dose data were available, the expected steady-state trough (from single-dose kinetics) was less than the mea-VOL. 37, 1993 on December 29, 2017 by guest http://aac.asm.org/ Downloaded from ANTIMICROB. AGENTS CHEMOTHER. sured steady-state trough (2.6 and 4.0 ,uM for 6-and 10-mg/ kg-dose groups, respectively). This is consistent with studies of adults for whom significant ribavirin accumulation in plasma (RBC/plasma ratio, 63:1) was observed with twicedaily dosing at steady state (18) . As described by Laskin et al., the greater-than-expected steady-state troughs are related to the accumulation of ribavirin into RBC.
It should be noted that all of the participants in this study were older than 1 year of age. Since the pharmacokinetic parameters for children during the first few weeks or months of life may be considerably different from those for older children, further studies will be needed to define the kinetics of systemic ribavirin in infants. The sample size of this study was too small to determine whether there were age-related changes in pharmacokinetics within the study population.
The maximum tolerated dose of ribavirin in adults has been estimated to be approximately 2,400 mg/day (approximately 34 mg/kg), with dose-limiting toxicities such as neu- rologic and hematologic abnormalities (17, 31) . Ribavirin doses ranging from 600 to 1,200 mg/day (approximately 9 to 17 mg/kg/day) are generally well tolerated in adult HIVinfected patients with HIV-associated symptoms that are mild to moderate (10, 17, 18, 29, 31) .
The study reported here demonstrates that once-daily oral administration of ribavirin at doses of 6 to 10 mg/kg for 60 days appears to be safe and well tolerated in This approach has theoretical advantages, including the reduction of drug toxicity by using lower exposures to individual agents, the enhancement of antiretroviral activity by using agents that are synergistic or additive when used in combination, and the prevention of the development of drug resistance. Initial studies of ribavirin demonstrated that it was antagonistic when used in combination with zidovudine or 2'3'-dideoxycytidine. Recent information, however, has demonstrated that ribavirin enhances the activity of purine analogs such as ddl (4) . Concentrations of ribavirin of 2.5 to 10 ,uM appear to demonstrate the maximum enhancing effect on the anti-HIV activity of ddI (2, 4) . This suggests that ribavirin may still play a role in combination chemotherapy for HIV infection.
Although the role of ribavirin as an antiretroviral agent is uncertain, the drug may have potential in the treatment of serious childhood viral illnesses in HIV-infected pediatric patients. Recent epidemiologic data indicate that the incidence of measles is increasing dramatically, especially in urban settings. Despite vaccination and/or immunoglobulin, the potential for fatal cases of measles exists in children with HIV infection (16, 19) . Three symptomatic children with moderate to advanced HIV disease who were monitored at Children's Hospital of New Jersey have died of measles during the past year. In addition, HIV-infected children with measles virus identified in central nervous system tissue have been reported, suggesting that chronic measles virus infection may occur in these children (33) . Ribavirin's activity against measles virus makes it potentially useful in the treatment of children with acute measles; theoretically, ribavirin may also be useful in the prophylaxis of children who have been exposed to measles virus. Oral dosing of ribavirin has been reported to be of benefit in the treatment of measles in studies performed outside the United States; doses of 10 mg/kg were associated with reduction of duration and severity of clinical manifestations without evidence of hematologic or other toxicities (12) .
The data presented here suggest that the pharmacokinetics and safety profile of systemically administered ribavirin in symptomatic, HIV-infected pediatric patients are similar to those reported for adults. Determination of the value of ribavirin for the treatment of HIV and/or other viral illnesses that occur in HIV-infected children awaits further study.
